Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
André J ScheenPublished in: Expert review of clinical pharmacology (2023)
Bridging the gap between evidence-based cardiovascular protection with GLP-1RAs and SGLT2is and their underuse in daily clinical practice in patients with T2DM at high risk is crucial from a public health viewpoint. However, the task appears hazardous and the goal not attained considering the current failure. Education of specialists/primary care physicians and patients is critical. Multifaceted and coordinated interventions involving all actors (physicians, patients and broadly health care system) must be implemented to stimulate the adoption of these cardioprotective antihyperglycemic medications as part of routine cardiovascular care among patients with T2DM.
Keyphrases
- primary care
- end stage renal disease
- public health
- healthcare
- clinical practice
- ejection fraction
- newly diagnosed
- chronic kidney disease
- quality improvement
- physical activity
- palliative care
- prognostic factors
- type diabetes
- metabolic syndrome
- skeletal muscle
- pain management
- adipose tissue
- weight loss
- patient reported
- affordable care act
- health insurance
- glycemic control